Mendioza-Contreras JR, García-Álvarez J

Language: Spanish
References: 25
Page: 187-192
PDF size: 140.13 Kb.

ABSTRACT

In Mexico as well an in other countries the epidemiologic reports indicate that the chronic deceases still occupied the first place in morbidity and mortality. Of all of them, type 2 diabetes mellitus (T2DM) is one with the more growing incidence in adult and productive population. Prevalence of T2DM in 2002 was 2.8% word wide and is estimated that it will increase to 4.4% in 2030, in every group of age and even if risks factors such as obesity maintain constant; mainly because habits such as hypercaloric diets and sedentary. In 2011 there were 366,000,000 diabetics reported worldwide and is expected to be approximately about 522,000,000 in 2030. Such situation forces us to take initiatives with the purpose of offering treatments that would give an adequate control, making of it a priority in public health. More than 60% of the people with T2DM are obese and that is why losing weight procedures are an attractive but defying therapeutic option. Gastric bypass (GB) is associated to higher rates of hyperglycemia remission, important fasting basal glucose levels reduction and diminish HbA1c compare to medical treatment by itself. So, when pharmaceutical and conductual interventions fail, metabolic surgery is and efficient possibility of T2DM full remission and offer a unique opportunity to better understand its pathophysiology.

REFERENCES

1. Olaiz G. Encuesta Nacional de Salud y Nutrición 2006. Instituto Nacional de Salud Pública 2006.

2. Mitka M. Bariatric surgery continues to show benefits for patients with diabetes. JAMA 2012; 307(18): 1901-02.

3. Dixon JB, et al. Bariatric surgery for type 2 diabetes. Lancet 2012; 379: 2300-11.

4. Rubino F, et al. Metabolic surgery: the role of the gastrointestinal tract in diabetes mellitus. Nat Rev Endocrinol 2010; 6(2): 102-09.

5. American Diabetes Association. Position Statement: Standards of Medical Care in Diabetes-2012. Diabetes Care 2012; 35(Suppl. 1): S11-S63.

6. Dixon JB. Bariatric surgery: an IDF statement for obese type 2 diabetes. Diabet Med 2011; 28(6): 628-42.

7. Schauer PR, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012; 366(17): 1567-76.

8. Mingrone G, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012; 366(17): 1577-85.

9. Anvari M. Is type 2 diabetes a surgical disease? Can J Surg 2007; 50(4): 249-50.

10. Scheen AJ, et al. Bariatric surgery in patients with type 2 diabetes: benefits, risks, indications and perspectives. Diabetes Metab 2009; 35(6): 537-43.

11. Spector D, et al. Neuro-modulation and bariatric surgery for type 2 diabetes mellitus. Int J Clin Pract 2010; 64(166): 53-58.

12. Suzuki K, et al. The gut hormones in appetite regulation. J Obes 2011; 2011: 528401.

13. Laferrère B, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 2008; 93(7): 2479-85.

14. Rubino F. Bariatric surgery: effects on glucose homeostasis. Curr Opin Clin Nutr Metab Care 2006; 9(4): 497-507.

15. Lim EL, et al. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011; 54(10): 2506-14.

16. Hage MP, et al. Role of gut-related peptides and other hormones in the amelioration of type 2 diabetes after Roux-en-Y gastric bypass surgery. ISRN Endocrinology; 2012; 1-13.

17. http://bioportal.bioontology.org/ontologies/46604/ ?p=terms&conceptid=CL%3A0002284

18. Wiedmer P, et al. Ghrelin, obesity and diabetes. Nat Clin Pract Endocrinol Metab 2007; 3(10): 705-12.

19. Laferrère B, et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 2007; 30(7): 1709-16.

20. Korner J, et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obes (Lond) 2009; 33(7): 786-95.

21. Andreelli F, et al. What can bariatric surgery teach us about the pathophysiology of type 2 diabetes? Diabetes Metab 2009; 35(6): 499-507.

22. Mingrone G, et al. Mechanisms of early improvement/ resolution of type 2 diabetes after bariatric surgery. Diabetes Metab 2009; 35(6): 518-23.

23. Laville M. Bariatric surgery for diabetes treatment: why should we go rapidly to surgery. Diabetes Metab 2009; 35(6): 562-63.

24. Varela JE. Bariatric surgery: a cure for diabetes? Curr Opin Clin Nutr Metab Care 2011; 14(4): 396-401.

25. Suzuki K, et al. Obesity and appetite control. Exp Diabetes Res 2012; 2012: 824305.